文献速递鼻科

两项3期临床试验SINUS-24和SINUS-52中慢性鼻窦炎伴鼻息肉患者2型炎症特征的发生率及度普利尤单抗疗效

Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
PubMed 文献 · Int Forum Allergy Rhinol · 2023-08-22

该分析基于SINUS-24/-52两项3期试验,采用六种2型炎症定义评估慢性鼻窦炎伴鼻息肉患者的2型炎症比例及度普利尤单抗疗效。基线时多数患者符合2型炎症特征(64.2%-95.3%)。度普利尤单抗在各定义下均显示稳健疗效,第24周和第52周达到临床意义改善的OR范围分别为NPS 11.9-14.9/19.0-36.6、NC 6.5-9.6/7.6-12.1、LoS 12.2-17.8/9.2-33.5(均p<0.0001)。

要点

  • 基线时多数慢性鼻窦炎伴鼻息肉患者存在2型炎症特征,各定义下比例为64.2%-95.3%。
  • 第24周度普利尤单抗 vs 安慰剂达到NPS临床意义改善的OR为11.9-14.9(各2型定义下)。
  • 第52周OR范围相似或更大:NPS 19.0-36.6,NC 7.6-12.1,LoS 9.2-33.5(均p<0.0001)。

核心结论

  • SINUS研究中多数慢性鼻窦炎伴鼻息肉患者存在2型炎症。
  • 度普利尤单抗在不同2型炎症定义下均表现出稳健疗效,与其作为白细胞介素-4和白细胞介素-13信号抑制剂的特性一致。

研究设计与样本

  • 国际SINUS-24/-52试验(NCT02912468/NCT02898454)的事后分析。
  • 采用六种2型炎症定义:≥150个嗜酸性粒细胞/μL或总IgE≥100 IU/mL且合并2型疾病;≥150个嗜酸性粒细胞/μL或总IgE≥100 IU/mL;≥150个嗜酸性粒细胞/μL;≥250个嗜酸性粒细胞/μL或总IgE≥100 IU/mL;合并哮喘或≥300个嗜酸性粒细胞/μL;存在合并2型疾病。
  • 计算度普利尤单抗 vs 安慰剂从基线至第24周(合并SINUS-24/-52)和第52周(SINUS-52)达到临床意义改善(≥1分)的OR,评估鼻息肉评分(NPS,范围0-8)、鼻塞/阻塞评分(NC,0-3)和嗅觉丧失评分(LoS,0-3)。

主要发现

  • 基线时(n=724)多数患者在各定义下均显示2型炎症特征,比例为64.2%-95.3%。
  • 第24周,各2型定义下NPS临床意义改善的OR范围为11.9-14.9,NC为6.5-9.6,LoS为12.2-17.8(均p<0.0001)。
  • 第52周OR范围相似或更大:NPS 19.0-36.6,NC 7.6-12.1,LoS 9.2-33.5(均p<0.0001)。

关键数值与推荐

  • 2型炎症定义:≥150个嗜酸性粒细胞/μL或总IgE≥100 IU/mL且合并2型疾病;≥150个嗜酸性粒细胞/μL或总IgE≥100 IU/mL;≥150个嗜酸性粒细胞/μL;≥250个嗜酸性粒细胞/μL或总IgE≥100 IU/mL;合并哮喘或≥300个嗜酸性粒细胞/μL;存在合并2型疾病。
  • 临床意义改善定义为NPS、NC或LoS较基线改善≥1分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This post hoc analysis of the international SINUS-24/-52 trials (NCT02912468/NCT02898454) aimed to assess dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) according to different definitions of type 2 inflammatory signature. METHODS: Six definitions of type 2 inflammation were used: ≥150 eosinophils/μL or total immunoglobulin E (IgE) ≥100 IU/mL with a coexisting type 2 condition; ≥150 eosinophils/μL or total IgE ≥100 IU/mL; ≥150 eosinophils/μL; ≥250 eosinophils/μL or total IgE ≥100 IU/mL; coexisting asthma or ≥300 eosinophils/μL; presence of a coexisting type 2 condition. Odds ratios (ORs; dupilumab vs. placebo) for achieving clinically meaningful improvement (≥1 point) from baseline to week 24 (pooled SINUS-24/-52) and week 52 (SINUS-52) were calculated for nasal polyp score (NPS; range 0-8), nasal congestion/obstruction score (NC; 0-3), and loss of smell score (LoS; 0-3). RESULTS: At baseline (n = 724), most patients displayed a type 2 inflammatory signature across definitions (64.2%-95.3%). At week 24, ORs for clinically meaningful improvement ranged from 11.9 to 14.9 for NPS across type 2 definitions, 6.5-9.6 for NC, and 12.2-17.8 for LoS (all p < 0.0001). OR ranges were similar or greater at week 52: 19.0-36.6, 7.6-12.1, and 9.2-33.5, respectively (all p < 0.0001). CONCLUSION: Most patients with CRSwNP in the SINUS study had type 2 inflammation. Dupilumab demonstrated robust efficacy across definitions of type 2 inflammation, consistent with its profile as an inhibitor of Interleukin-4 and Interleukin-13 signaling, key and central drivers of type 2 inflammation in CRSwNP. KEY POINTS: This study assessed type 2 inflammation prevalence and dupilumab efficacy in chronic rhinosinusitis with nasal polyps according to algorithm-defined type 2 inflammation Dupilumab efficacy was similar across all type 2 definitions.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Bachert C, Khan AH, Lee SE, et al. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52. Int Forum Allergy Rhinol. 2023. PMID: 37548085. doi:10.1002/alr.23249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。